Evidence map›Paper›PMID 41340973›Full record

ArticleCureus2025

Hemorrhagic Events Associated With Direct Oral Anticoagulants: Frequency and Management.

Mohamed Ztati, Oussama Zaanouny, Ayoub Nasim, Mustapha El Hattaoui

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohamed ZtatiCardiology, Hospital Arrazi, Centre Hospitalo-Universitaire (CHU) Mohammed VI, Université Cadi Ayyad (UCA) Faculty of Medicine and Pharmacy in Marrakech, Marrakech, MAR.
Oussama ZaanounyCardiology, Hospital Arrazi, Centre Hospitalo-Universitaire (CHU) Mohammed VI, Université Cadi Ayyad (UCA) Faculty of Medicine and Pharmacy in Marrakech, Marrakech, MAR.
Ayoub NasimCardiology, Hospital Arrazi, Centre Hospitalo-Universitaire (CHU) Mohammed VI, Université Cadi Ayyad (UCA) Faculty of Medicine and Pharmacy in Marrakech, Marrakech, MAR.
Mustapha El HattaouiCardiology, Hospital Arrazi, Centre Hospitalo-Universitaire (CHU) Mohammed VI, Université Cadi Ayyad (UCA) Faculty of Medicine and Pharmacy in Marrakech, Marrakech, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Direct oral anticoagulants (DOACs) have transformed anticoagulation strategies, yet bleeding complications remain a significant concern, particularly in elderly patients with polypharmacy. Methodology In this three-year, cross-sectional study conducted at a tertiary cardiology center in Morocco, we analyzed 35 cases of non-traumatic DOAC-related bleeding. Results The mean patient age was 67.5 years, and 89% were on multiple medications. Rivaroxaban was the most prescribed DOAC (74%), and gastrointestinal bleeding was the most common presentation (46%), followed by intracerebral hemorrhage and epistaxis (14% each). Major bleeding occurred in 34% of cases; however, no specific reversal agents were used. Despite resource limitations, outcomes were favorable in 94% of patients, with only two deaths recorded. Conclusions These real-world findings highlight the importance of individualized DOAC management, structured medication reviews, and improved access to reversal agents. In resource-limited settings, standardized protocols and clinician training are crucial to bridge the gap between guideline recommendations and everyday clinical practice.

Indexed as

antithrombotic therapybleeding managementdirect-acting oral anticoagulants (doacs)hemorrhagic complicationsoral anticoagulants

Identifiers

PMID41340973
PMCPMC12671894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.